Key stats
About Putnam BioRevolution ETF
Expense ratio
0.71%
Home page
Inception date
Sep 29, 2022
SYNB holds a high conviction portfolio that provides exposure to bio revolution, which involves technological advancements in the biological and life sciences that contribute to transforming the economy. The fund primarily invests in (i) technology enablers that provide the materials, equipment, and knowledge to enable biological production, (ii) disruptive biotech or synthetic bio companies, and (iii) other firms positioned to benefit from the theme. The funds exposure goes beyond healthcare, as it may also invest in other sectors that are likely to be positively impacted, such as consumer discretionary, consumer staples, materials, and agriculture. SYNB's portfolio typically comprises growth stocks. In selecting stocks, the fund manager considers valuation, financial strength, growth potential, industry position, projected future earnings, cash flows, and dividends.
Classification
What's in the fund
Exposure type
Health Technology
Process Industries
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.